CoChat

Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management

Open access

The DOI matches its Crossref record; 773 of the 831 references it cites were found in a registry or an index; 177 of the 559 sources its claims cite were checked for support.

Abstract

Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders affecting cortisol biosynthesis. Reduced activity of an enzyme required for cortisol production leads to chronic overstimulation of the adrenal cortex and accumulation of precursors proximal to the blocked enzymatic step. The most common form of CAH is caused by steroid 21-hydroxylase deficiency due to mutations in CYP21A2. Since the last publication summarizing CAH in Endocrine Reviews in 2000, there have been numerous new developments. These include more detailed understanding of steroidogenic pathways, refinements in neonatal screening, improved diagnostic measurements utilizing chromatography and mass spectrometry coupled with steroid profiling, and improved genotyping methods. Clinical trials of alternative medications and modes of delivery have been recently completed or are under way. Genetic and cell-based treatments are being explored. A large body of data concerning long-term outcomes in patients affected by CAH, including psychosexual well-being, has been enhanced by the establishment of disease registries. This review provides the reader with current insights in CAH with special attention to these new developments.

Overview

CoChat Summary

TL;DR

This review summarizes current understanding of congenital adrenal hyperplasia (CAH), predominantly 21-hydroxylase deficiency (21OHD), covering steroidogenesis, genetics, diagnosis, management, and long-term outcomes. It emphasizes a phenotypic continuum, newer biomarkers and therapies, and persistent evidence gaps in treatment and surgical care.

Key findings

  • 21OHD accounts for approximately 90–99% of CAH; classic CAH incidence is about 1 in 14,000 to 18,000 by newborn screening, while nonclassic (NC) CAH is estimated at ~1 in 200 in the Caucasian population.
  • Genotype correlates with the less severely impaired CYP21A2 allele: 96% of individuals with two Group 0 alleles have salt-wasting CAH, whereas 97% of those with at least one Group C allele have NC CAH; residual enzyme activity is ~1–5% in simple virilizing and ~20–50% in NC CAH.
  • Long-term sequelae include testicular adrenal rest tumors (TARTs) in males (reported prevalence 14–86%, average 25% in adolescents and 46% in men), adrenal masses in ~20–30% of adults, and increased mortality; adrenal crises caused 42% of deaths in a Swedish cohort, with mean age at death 54.8 years versus 72.8 years in controls.
  • Newer concepts include 11-oxo-androgens such as 11-ketotestosterone as biomarkers, the backdoor pathway to dihydrotestosterone, and novel therapies (CRHR1 antagonists, abiraterone, modified-release hydrocortisone, gene/cell-based approaches), though many lack peer-reviewed long-term outcomes.

Methods

  • Narrative, multi-authored review resulting from a planned European CAH Symposium postponed due to the COVID-19 pandemic; it covers pathophysiology, diagnostics, management, long-term sequelae, developing-country challenges, and future directions.
  • Evidence base is a synthesis of published literature, clinical guidelines (including the 2018 Endocrine Society guideline), registries, observational studies, meta-analyses, and clinical trials; no primary patient cohort or systematic search is described.
  • Main analysis is narrative synthesis, with tables and figures summarizing incidence, allele frequencies, treatment dosing, monitoring, and prenatal dexamethasone outcomes.

Limitations

  • Stated: there are no large-scale prospective randomized trials for any therapies discussed; evidence is generally low or moderate quality and rests partly on expert opinion, values, and preferences.
  • Stated: no evidence-based guidelines for surgical management exist, and there are no studies comparing different feminizing surgery techniques or early versus late surgery; genotype-phenotype correlations are strong but not absolute, and many neuroimaging studies are hindered by small sample size.
  • Evident: as a narrative review, it does not report a systematic search strategy, formal risk-of-bias assessment, or quantitative synthesis; conclusions depend on the cited literature and expert consensus.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1210/endrev/bnab016

Cites

773 of 773 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

86 Valid · 78 Not valid · 186 Not checked · 76 Own results and interpretations

207 more claims · 72 with their cited sources checked

Create a free account to see all 426 claims and to verify the 50 references still open.

See all claims — free account
  • It may state two separate claims as one. 172
  • Probably not a substantial claim. 64

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

2 of 2

Citations

Cites

Items 601–773 of 773

Research works printed but not linked: 2

  1. McCann-Crosby, 2014, Non classic CAH; targets of treatment and transition, Pediatr Endocr Rev., 12, 224
  2. Auchus, 2012, Abiraterone acetate added to physiologic hydrocortisone dosing safely controls androgen excess in adult women with classical 21-hydroxylase deficiency, Endocr Rev., 33, SUN-LB2

Cited by

See all 556

Metadata

Authors
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., Krone, N., Merke, D. P., Miller, W. L., Nordenström, A., Reisch, N., Sandberg, D. E., Stikkelbroeck, N. M. M. L., Touraine, P., Utari, A., Wudy, S. A., & White, P. C.
Affiliations
  • Department of Pediatric Endocrinology, Radboud University Medical Centre, Amalia Childrens Hospital, Nijmegen, The Netherlands
  • Northwell Health (US)
  • University of Glasgow (GB)
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • University of Michigan (US)
  • Karolinska University Hospital (SE)
  • University of Bern (CH)
  • Queen Mary University of London (GB)
  • Technische Universität Dresden (DE)
  • Radboud University Medical Center (NL)
  • University Hospital Carl Gustav Carus (DE)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
  • University of California, San Francisco (US)
  • LMU Klinikum (DE)
  • Sorbonne Université (FR)
  • Diponegoro University (ID)
  • Justus-Liebig-Universität Gießen (DE)
  • The University of Texas Southwestern Medical Center (US)
Corresponding author
White, Perrin C
Venue
Endocrine Reviews
Published
2021-05-07
Volume
43
Issue
1
Pages
91-159
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W4229036110
Cited by
556
References
831
Citations by year
2026: 102 · 2025: 125 · 2024: 149 · 2023: 97 · 2022: 68 · 2021: 14
FWCI
8.59
Type
journal article
Language
en
Open access
Locations
  • Endocrine Reviews (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
  • Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
Funders
National Institutes of Health (U01-HD083493)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
congenital adrenal hyperplasia, 21-hydroxylase deficiency, CYP21A2 mutations, cortisol production, steroidogenic pathway, newborn screening, steroid profiling, genotyping, cell therapy, gene therapy, long-term outcomes, disease registries

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.